CJC-1295Growth-hormone secretagogue · research
CJC-1295 was designed to prolong growth hormone-releasing hormone activity. Early human work shows hormonal effects, but does not establish the muscle, recovery or anti-ageing outcomes often attached to the name.
What is CJC-1295?
CJC-1295 is a growth hormone-releasing hormone analogue. The long-acting form studied with a drug-affinity complex (DAC) should be distinguished from products marketed as “without DAC”.
How it works
The studied DAC form binds albumin to prolong exposure and stimulates growth-hormone and downstream IGF-1 signalling. 1 2
Effects studied
Growth-hormone and IGF-1 responses
Two short randomised trials in healthy adults, lasting 28 and 49 days, found sustained increases in growth hormone and IGF-1. They measured hormonal activity, not stronger muscles, better sleep or faster healing. 1
Evidence: Pharmacological activity is not evidence of improved strength, recovery or longevity.
The idea behind a longer hormone signal
Natural GHRH acts briefly. CJC-1295 was developed to extend that stimulation, and the early human trials showed sustained GH and IGF-1 responses. That is a meaningful proof of pharmacological activity and explains the research interest. Whether the longer signal leads to useful changes in strength, recovery or health is a further question; these trials did not measure those benefits. 1
Evidence: Early human pharmacology; measured hormone responses, clinical benefits remain an open question.
What does the evidence show?
Early human hormone studies; FDA safety notice checked
First check which molecule is meant
The long-acting CJC-1295 studied in early trials includes an albumin-binding modification often called DAC. Products marketed as “CJC-1295 without DAC” may instead refer to a shorter-acting modified GHRH fragment. Those labels should not be treated as interchangeable clinical evidence.
What the human experiments show
Two short randomised trials in healthy adults, lasting 28 and 49 days, found sustained increases in growth hormone and IGF-1. They measured hormonal activity, not stronger muscles, better sleep or faster healing. 1
A separate study examined the pattern of growth-hormone release. Preserved hormone pulses do not establish a long-term health benefit. 2
Why combinations are a separate question
Combining a GHRH analogue with a ghrelin-receptor agonist can change the hormonal response. That mechanistic rationale does not validate a marketed “stack”. The combined product, exposure and adverse effects need their own assessment. Individual hormone measurements cannot establish how the combination will perform.
The idea behind a longer hormone signal
Natural GHRH acts briefly. CJC-1295 was developed to extend that stimulation, and the early human trials showed sustained GH and IGF-1 responses. That is a meaningful proof of pharmacological activity and explains the research interest. Whether the longer signal leads to useful changes in strength, recovery or health is a further question; these trials did not measure those benefits. 1
What the safety notice adds
The FDA identifies limited safety information and concerns about immune reactions and peptide impurities. It also describes serious reactions associated with CJC-1295, including increased heart rate and systemic vasodilation. A longer-lasting signal may be convenient, but it can also complicate an unwanted response. 3
Safety & status
The FDA notes limited safety information and concerns about immune reactions and impurities. Reported serious events include increased heart rate and systemic vasodilatory reactions. 3
Country and product status
FDA compounding safety information checked. EU and Swiss authorisation has not been established by this draft.
Frequently asked questions
Does a higher IGF-1 level demonstrate better recovery?
No. A hormone measurement and a meaningful recovery outcome require different evidence.
Are DAC and “no DAC” products interchangeable?
No. The identity and duration of action can differ, so findings from the studied DAC preparation should not be transferred automatically.
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Teichman et al. (2006): Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 Primary research · PubMed abstract; full paper and supplements not reviewed; checked 2026-10-29
- Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295 Primary research · Indexed primary abstract; not full text; checked 2026-10-29
- FDA: Compounding substances with potential significant safety risks US regulator · Relevant substance entry; US safety notice, not an EU authorisation assessment; checked 2026-10-29
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.